Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases. Its three approved medicines are LIVMARLI (maralixibat), for cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis; Ctexli… From the company’s description.
Over the twelve months to Sep 30, 2026, Mirum Pharmaceuticals, Inc. reported revenue of $670.78M, up 42.2% from a year earlier, and a net loss of $903.88M. Its operating margin was −133.6%, and operations used $271.26M in cash. In fiscal 2025, it reported revenue of $521.31M, up 54.7% from fiscal 2024, and a net loss of $23.36M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Mirum Pharmaceuticals, Inc. does
In the company’s own words
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases. Its three approved medicines are LIVMARLI (maralixibat), for cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis; Ctexli (chenodiol), for adults with cerebrotendinous xanthomatosis; and Cholbam (cholic acid), for bile acid synthesis disorders and as adjunctive treatment for peroxisomal disorders, including Zellweger spectrum disorder. Mirum sells these medicines directly in the United States, Canada and certain European countries, and uses licensing and distribution partners in other markets. Its clinical pipeline includes volixibat for primary sclerosing cholangitis and primary biliary cholangitis, brelovitug for chronic hepatitis D infection, and MRM-3379 for fragile X syndrome; it is also studying LIVMARLI in additional rare cholestatic conditions. The company acquired the Cholbam and chenodiol assets in 2023 and acquired Bluejay Therapeutics, including brelovitug, in January 2026.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- FOSTER CITY, CA
- Fiscal year end
- December
- CIK
- 1759425
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Mirum Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Mirum Pharmaceuticals, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Mirum Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Mirum Pharmaceuticals, Inc.’s bonds, as funds hold them
Funds report holding 2 issues of Mirum Pharmaceuticals, Inc.’s debt, $126.32M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.00%, maturing 2029 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Mirum Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Mirum Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Mirum Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”